Lung Cancer Market, 2025-2034 | Trends Report

Lung Cancer Market - By Diagnostics and Therapeutics, By Indication, By End Use - Global Forecast, 2025 – 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600&nbsp;synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Rising prevalence of lung cancer globally

3.2.1.2&nbsp;&nbsp;&nbsp; Technology advancements in diagnostics and screening

3.2.1.3&nbsp;&nbsp;&nbsp; Increasing adoption of targeted and immune therapies

3.2.1.4&nbsp;&nbsp;&nbsp; Rising demand for minimally invasive procedures

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost of treatment

3.2.2.2&nbsp;&nbsp;&nbsp; Dearth of well-skilled and trained oncologists and radiologists

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Trump administration tariffs

3.5.1&nbsp;&nbsp;&nbsp; Impact on trade

3.5.1.1&nbsp;&nbsp;&nbsp; Trade volume disruptions

3.5.1.2&nbsp;&nbsp;&nbsp; Retaliatory measures

3.5.2&nbsp;&nbsp;&nbsp; Impact on the Industry

3.5.2.1&nbsp;&nbsp;&nbsp; Supply-side impact (raw materials)

3.5.2.1.1&nbsp;&nbsp;&nbsp; Price volatility in key materials

3.5.2.1.2&nbsp;&nbsp;&nbsp; Supply chain restructuring

3.5.2.1.3&nbsp;&nbsp;&nbsp; Production cost implications

3.5.2.2&nbsp;&nbsp;&nbsp; Demand-side impact (selling price)

3.5.2.2.1&nbsp;&nbsp;&nbsp; Price transmission to end markets

3.5.2.2.2&nbsp;&nbsp;&nbsp; Market share dynamics

3.5.2.2.3&nbsp;&nbsp;&nbsp; Consumer response patterns

3.5.3&nbsp;&nbsp;&nbsp; Key companies impacted

3.5.4&nbsp;&nbsp;&nbsp; Strategic industry responses

3.5.4.1&nbsp;&nbsp;&nbsp; Supply chain reconfiguration

3.5.4.2&nbsp;&nbsp;&nbsp; Pricing and product strategies

3.5.4.3&nbsp;&nbsp;&nbsp; Policy engagement

3.5.5&nbsp;&nbsp;&nbsp; Outlook and future considerations

3.6&nbsp;&nbsp;&nbsp; Future market trends

3.7&nbsp;&nbsp;&nbsp; Lung cancer epidemiology

3.8&nbsp;&nbsp;&nbsp; Reimbursement scenario

3.9&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.10&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Diagnostics and Therapeutics, 2021 &ndash; 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Diagnostics

5.2.1&nbsp;&nbsp;&nbsp; Bronchoscopy

5.2.2&nbsp;&nbsp;&nbsp; Molecular testing

5.2.3&nbsp;&nbsp;&nbsp; Imaging

5.2.4&nbsp;&nbsp;&nbsp; Other diagnostics

5.3&nbsp;&nbsp;&nbsp; Therapeutics

5.3.1&nbsp;&nbsp;&nbsp; Non-invasive therapy

5.3.1.1&nbsp;&nbsp;&nbsp; By type

5.3.1.1.1&nbsp;&nbsp;&nbsp; Chemotherapy

5.3.1.1.2&nbsp;&nbsp;&nbsp; Targeted therapy

5.3.1.1.3&nbsp;&nbsp;&nbsp; Immunotherapy

5.3.1.1.4&nbsp;&nbsp;&nbsp; Other non-invasive therapies

5.3.1.2&nbsp;&nbsp;&nbsp; By route of administration

5.3.1.2.1&nbsp;&nbsp;&nbsp; Oral

5.3.1.2.2&nbsp;&nbsp;&nbsp; Parenteral

5.3.2&nbsp;&nbsp;&nbsp; Minimally invasive therapy

5.3.2.1&nbsp;&nbsp;&nbsp; Radiofrequency ablation

5.3.2.2&nbsp;&nbsp;&nbsp; Microwave ablation

5.3.2.3&nbsp;&nbsp;&nbsp; Thermal/cryoablation

5.3.2.4&nbsp;&nbsp;&nbsp; Other minimally invasive therapies

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Indication, 2021 &ndash; 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Non-small cell lung cancer

6.3&nbsp;&nbsp;&nbsp; Small cell lung cancer

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End Use, 2021 &ndash; 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Hospitals

7.3&nbsp;&nbsp;&nbsp; Diagnostic laboratories

7.4&nbsp;&nbsp;&nbsp; Specialty clinics

7.5&nbsp;&nbsp;&nbsp; Other end use

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Netherlands

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; India

8.4.3&nbsp;&nbsp;&nbsp; Japan

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Argentina

8.6&nbsp;&nbsp;&nbsp; Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; UAE

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; AdvaCare Pharma

9.2&nbsp;&nbsp;&nbsp; Biodesix

9.3&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company

9.4&nbsp;&nbsp;&nbsp; CHEPLAPHARM Group

9.5&nbsp;&nbsp;&nbsp; Cleveland Clinic

9.6&nbsp;&nbsp;&nbsp; F. Hoffmann La Roche

9.7&nbsp;&nbsp;&nbsp; Memorial Sloan Kettering Cancer Center

9.8&nbsp;&nbsp;&nbsp; Merck &amp; Co.

9.9&nbsp;&nbsp;&nbsp; Pfizer

9.10&nbsp;&nbsp;&nbsp; Rutgers Health Sun Pharmaceutical

9.11&nbsp;&nbsp;&nbsp; Sun Pharmaceuticals

9.12&nbsp;&nbsp;&nbsp; Teva Pharmaceuticals

9.13&nbsp;&nbsp;&nbsp; UPMC

9.14&nbsp;&nbsp;&nbsp; Weill Cornell Medicine

Lung Cancer Market

Get a free sample of this report

Industries

Information

Link

Global Headquarters